Biocept ($BIOC) usually fights cancer due to molecular diagnostics. Today it announced that it’s expanding the availability of its testing services for the COVID-19 after entering into an extensive agreement with Multiplan, Inc. This development will make Biocept’s COVID-19 tests available to consumers with access to the PHCS and MultiPlan networks. Simply put, these are MultiPlan’s national primary and complementary networks.

Why an agreement MultiPlan Inc.

MultiPlan is known for its financial expertise in healthcare. For decades, the company has been advising on financial risk analysis, payment integrity and network solutions to improve primary preferred providers (PPO) for hospitals and healthcare facilities. Multiplan is aware that COVID-19 tests are currently being introduced at breakneck speed, including many hasty and opportunistic market players. Everything healthcare providers know about the virus is recently acquired knowledge, which increases the risks for both producer and user. By combining knowledge and experience, Biocept and Multiplan want to guarantee that this is a COVID-19 test in which quality and management are of paramount importance.

Today, more than 1 million healthcare providers participate in MultiPlan’s networks, adding the 60 million health insurance members who have access to the company’s services. Part of this group may already be familiar with Biocept, as MultiPlan has made Biocept’s Target Selector™ available in the past five years.

Preparation for this extensive agreement

Biocept has a waiting time of up to 48 hours to provide the test result to healthcare providers at a pre-determined price of $ 100 USD per test. The company operates in a highly advanced, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego. The molecular laboratory personnel are trained on a high level to work with the COVID-19 tests.

By implementing a new advanced online ordering system, test results will be available to the customer more quickly and the front-end onboarding process in the laboratory will be more efficient, increasing the testing capacity and lowering its costs. Biocept strives for testing performance, quality and customer service to be ideal to support providers and maintain compliance with state mandates.

Earlier this month, Biocept provided the COVID-19 testing service to various facilities in several states. The majority of the test results were reported within the predetermined 48 hours and its users were impressed with the fast turnaround times. It’s time to introduce the millions of healthcare providers and health insurance members to Biocept and their high-potential COVID-19 testing service.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.

By Omar